LEO Pharma A/S

Who: Sanofi/Formation Bio What: The French drugmaker has licensed gusacitinib, an oral dual JAK/SYK inhibitor. Why: The companies have several long-standing pacts already in place “focused on ide

Kymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa

Leo Pharma has posted a strong set of financials for the first quarter of 2025, “building on build on the momentum that we delivered in 2024,” CEO Christophe Bourdon has told Scrip . Revenues rose by

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova